Reducing prostaglandin E₂ production to raise cancer immunogenicity

Figures & data

Figure 1. COX-driven PGE₂ production by cancer cells fuels tumor-promoting inflammation and allows progressive tumor growth. Cancer cell-specific COX-deficiency alters the inflammatory profile at the tumor site increasing antitumor mediators and enabling immune-dependent tumor rejection.